Paul R Edick's Net Worth
$7.9 Million
Who is Paul R Edick?
Paul R Edick has an estimated net worth of $7.9 Million. This is based on reported shares across multiple companies, which include Xeris Biopharma Holdings, Inc., XERIS PHARMACEUTICALS INC, Sucampo Pharmaceuticals, Inc., Milestone Pharmaceuticals Inc., Neos Therapeutics, Inc., Iterum Therapeutics plc, NEWLINK GENETICS CORP, Durata Therapeutics, Inc., and PDL BIOPHARMA, INC..
SEC CIK
Paul R Edick's CIK is 0001531178
Past Insider Trading and Trends
2021 was Paul R Edick's most active year for acquiring shares with 10 total transactions. Paul R Edick's most active month to acquire stocks was the month of April. 2021 was Paul R Edick's most active year for disposing of shares, totalling 7 transactions. Paul R Edick's most active month to dispose stocks was the month of September. 2013 saw Paul R Edick paying a total of $749,000.00 for 112,000 shares, this is the most they've acquired in one year. In 2018 Paul R Edick cashed out on 46,484 shares for a total of $345,740.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Xeris Biopharma Holdings, Inc. (XERS) Snapshot price: $2.51
See RemarksPaul R Edick owns 3,788,064 units of Common Stock which is worth $9,508,040.64.acquired a total of 3,788,064 shares in Xeris Biopharma Holdings, Inc. at a cost of $608,934.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +65.56% | 1.5M |
—
|
—
| 3.79M |
Jan 31
| |||
Form 4
| +0.44% | 10K |
$2.38 | $23,794.00 | 2.29M |
Aug 9
| |||
Form 4
| +49.08% | 750K |
—
|
—
| 2.28M |
Jan 31
| |||
Form 4
| +1.33% | 20K |
$1.45 | $29,000.00 | 1.53M |
Dec 13
| |||
Form 4
| +7.10% | 100K |
$1.40 | $140,380.00 | 1.51M |
May 12
| |||
Form 4
| +74.25% | 600K |
—
|
—
| 1.41M |
Jan 3
| |||
Form 4
| +148.92% | 20K |
$2.28 | $45,664.00 | 33.43K |
Nov 15
| |||
Form 4
| +32.89% | 200K |
$2.08 | $415,760.00 | 808.06K |
Nov 11
| |||
Form 4
|
∞
| 621.49K |
—
|
—
| 621.49K |
Oct 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
XERIS PHARMACEUTICALS INC No price found
Chief Executive OfficerPaul R Edick used to own units in Common Stock but no longer holds any shares there. In the year 2018 Paul R Edick filed a total of 12 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -621.49K |
—
|
—
|
0
|
Oct 5
| |||
Form 4
| +54.73% | 225K |
—
|
—
| 636.13K |
Jan 29
| |||
Form 4
| +2.49% | 10K |
$4.06 | $40,551.00 | 411.13K |
Dec 9
| |||
Form 4
| +8.96% | 33K |
$3.00 | $99,000.00 | 401.13K |
May 8
| |||
Form 4
| +101.02% | 185K |
—
|
—
| 368.13K |
Jan 31
| |||
Form 4
| +12.26% | 20K |
$4.15 | $83,000.00 | 183.13K |
Feb 14
| |||
Form 4
| -5.67% | -9.80K |
$6.37 | -$62,432.37 | 163.13K |
Jan 31
| |||
Form 4
| +11.57% | 17.93K |
$8.55 | $153,283.27 | 172.94K |
Nov 25
| |||
Form 4
| +24.00% | 30K |
$9.12 | $273,585.00 | 155K |
Mar 11
| |||
Form 4
|
∞
| 125K |
—
|
—
| 125K |
Jan 31
| |||
Form 4
|
∞
| 13.43K |
—
|
—
| 13.43K |
Jun 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Sucampo Pharmaceuticals, Inc. No price found
InvestorPaul R Edick owns 19,830 units of Common Stock. Paul R Edick used to own units in Common Stock, Class A but no longer holds any shares there. In the year 2016 Paul R Edick filed a total of 5 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -14.93K |
$18.00 | -$268,740.00 |
0
|
Feb 13
| |||
Form 4/A
| +34.90% | 5.13K |
—
|
—
| 19.83K |
Jun 1
| |||
Form 4
| +52.35% | 5.13K |
—
|
—
| 14.93K |
Jun 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
∞
| 14.7K |
—
|
—
| 14.7K |
Aug 1
| |||
| No matching records found | |||||||||
Milestone Pharmaceuticals Inc. (MIST) Snapshot price: $1.46
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Neos Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||